A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer
-
- Yonenobu Yuki
- Department of Neurology, Toneyama National Hospital
-
- Ishijima Mikako
- Department of Thoracic Oncology, Toneyama Natoinal Hospital
-
- Toyooka Keiko
- Department of Neurology, Toneyama National Hospital
-
- Fujimura Harutoshi
- Department of Neurology, Toneyama National Hospital
Bibliographic Information
- Other Title
-
- 肺扁平上皮癌に対するpembrolizumab投与後に髄膜脳炎を来した1例
Search this article
Description
<p>A 61-year-old man with squamous cell lung cancer was admitted to our hospital because of consciousness disturbance after treated with pembrolizumab. Cerebrospinal fluid examination revealed increased protein level (209.2 mg/dl) and lymphocytic pleocytosis(79/μl). He was diagnosed as a meningoencephalitis probably caused by an immune-related adverse event (irAE) of immune checkpoint inhibitors (ICIs), and was successfully treated with 1,000 mg methylprednisolone intravenously for 3 days twice and the consequent oral 1 mg/kg prednisolone. As ICIs, which activate the immune systems, are becoming important choices of the treatments against malignancies, we should keep the possibility of irAE in mind and, when needed, start the treatment as soon as possible.</p>
Journal
-
- Rinsho Shinkeigaku
-
Rinsho Shinkeigaku 59 (2), 105-108, 2019
Societas Neurologica Japonica
